Increased serum level of soluble vascular endothelial growth factor receptor-1 is associated with poor coronary collateralization in patients with stable coronary artery disease

Circulation Journal

Volumn 78, Issue 5, 2014, Pages 1191-1196

  Sun, Zhen ^a   Shen, Ying ^a   Lu, Lin ^a,b   Zhang, Rui Yan ^a   Pu, Li Jin ^a   Zhang, Qi ^a   Yang, Zheng Kun ^a   Hu, Jian ^a   Chen, Qiu Jing ^b   Shen, Wei Feng ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Collateral growth; Coronary artery disease; Diabetes mellitus; Soluble vascular endothelial growth factor receptor 1

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SCORING SYSTEM;

EID: 84899634483     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1143     Document Type: Article

References (45)

1. Meier P, Gloekler S, Zbinden R, Beckh S, de Marchi SF, Zbinden S, et al. Beneficial effect of recruitable collaterals: A 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation 2007; 116: 975-983.
2. Traupe T, Gloekler S, de Marchi SF, Werner GS, Seiler C. Assessment of the human coronary collateral circulation. Circulation 2010; 122: 1210-1220.
3. Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, Kaul S. An association between collateral flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327: 1825-1831.
4. Fujita M, Sasayama S. Coronary collateral growth and its therapeutic application to coronary artery disease. Circ J 2010; 74: 1283-1289.
5. Fujita M, Miyamoto S. Progress in the functional assessment of human coronary collateral circulation. Circ J 2012; 76: 297-298.
6. Clayton JA, Chalothorn D, Faber JE. Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia. Circ Res 2008; 103: 1027-1036.
7. Lahteenvuo JE, Lahteenvuo MT, Kivela A, Rosenlew C, Falkevall A, Klar J, et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 2009; 119: 845-856.
8. Kocaman SA, Arslan U, Tavil Y, Okuyan H, Abaci A, Cengel A. Increased circulating monocyte count is related to good collateral development in coronary artery disease. Atherosclerosis 2008; 197: 753-756.
9. Tokgozoglu L, Yorgun H, Gurses KM, Canpolat U, Ates AH, Tulumen E, et al. The association between circulating endothelial progenitor cells and coronary collateral formation. Atherosclerosis 2011; 219: 851-854.
10. Taniguchi T, Sawada T. Significance of measuring plasma vascular endothelial growth factor in patients with acute myocardial infarction. Circ J 2012; 76: 1331-1332.
11. Matsudaira K, Maeda K, Okumura N, Yoshikawa D, Morita Y, Mitsuhashi H, et al; Nagoya Acute Myocardial Infarction Study (NAMIS) Group. Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome: Results from the Nagoya Acute Myocardial Infarction Study. Circ J 2012; 76: 1509-1516.
12. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709.
13. Kaza E, Ablasser K, Poutias D, Griffiths ER, Saad FA, Hofstaetter JG, et al. Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium. Cardiovasc Res 2011; 89: 410-418.
14. Kishuku M, Nishioka Y, Abe S, Kishi J, Ogino H, Aono Y, et al. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property. J Immunol 2009; 183: 8176-8185.
15. Al-Ani B, Hewett PW, Cudmore MJ, Fujisawa T, Saifeddine M, Williams H, et al. Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells. Hypertension 2010; 55: 689-697.
16. Ikeda T, Sun L, Tsuruoka N, Ishigaki Y, Yoshitomi Y, Yoshitake Y, et al. Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing. Biochem J 2011; 436: 399-407.
17. Ito T, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009; 113: 2363-2369.
18. Pavlakovic H, Prof JB, Albuquerque R, Wilting J, Ambati J. Soluble VEGFR-2: An anti-lymphangiogenic variant of VEGF receptors. Ann NY Acad Sci 2010; 1207(Suppl 1): E7-E15.
19. Wada H, Satoh N, Kitaoka S, Ono K, Morimoto T, Kawamura T, et al. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis 2010; 208: 512-517.
20. Mouquet F, Cuilleret F, Susen S, Sautiere K, Marboeuf P, Ennezat PV, et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: Association with hyperglycemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 2009; 30: 840-849.
21. Takeda Y, Uemura S, Iwama H, Imagawa K, Nishida T, Onoue K, et al. Treatment with recombinant placental growth factor (PLGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J 2009; 73: 1674-1682.
22. Levin DC. Pathways and functional significance of the coronary collateral circulation. Circulation 1974; 50: 831-837.
23. Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50: 2264-2274.
24. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl 1): S5-S20.
25. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O'Brien PC, Melton LJ 3rd. The classification of diabetes by clinical and C-peptide criteria: A prospective population-based study. Diabetes Care 1997; 20: 198-201.
26. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
27. Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009; 206: 540-545.
28. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: Implications for patient selection (Multivessel Angioplasty Prognosis Study Group). Circulation 1990; 82: 1193-1202.
29. Hsu PC, Juo SH, Su HM, Chen SC, Tsai WC, Lai WT, et al. Predictor of poor coronary collaterals in chronic kidney disease population with significant coronary artery disease. BMC Nephrol 2012; 13: 98.
30. Kadi H, Ozyurt H, Ceyhan K, Koc F, Celik A, Burucu T. The relationship between high-density lipoprotein cholesterol and coronary collateral circulation in patients with coronary artery disease. J Invest Med 2012; 60: 808-812.
31. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, et al. Negative regulation of soluble flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-1797.
32. Sahinarslan A, Kocaman SA, Topal S, Ercin U, Bukan N, Yalcin R, et al. Relation between serum monocyte chemoattractant protein-1 and coronary collateral development. Coron Artery Dis 2010; 21: 455-459.
33. Ripa RS, Wang Y, Goetze JP, Jorgensen E, Johnsen HE, Taqil K, et al. Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease: Indicators of myocardial ischemic burden? Int J Cardiol 2007; 120: 181-187.
34. Ripa RS, Jørgensen E, Baldazzi F, Frikke-Schmidt R, Wang Y, Tybjaerg-Hansen A, et al. The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease. Scand J Clin Lab Invest 2009; 69: 722-728.
35. Keeley EC, Moorman JR, Liu L, Gimple LW, Lipson LC, Ragosta M, et al. Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS One 2011; 6: e21174, doi:10.1371/journal.pone.0021174.
36. Rocic P. Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome? Vascul Pharmacol 2012; 57: 179-186.
37. Werner GS, Richartz BM, Heinke S, Ferrari M, Figulla HR. Impaired acute collateral recruitment as a possible mechanism for increased cardiac adverse events in patients with diabetes mellitus. Eur Heart J 2003; 24: 1134-1142.
38. van Weel V, de Vries M, Voshol PJ, Verloop RE, Eilers PH, van Hinsbergh VW, et al. Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1383-1390.
39. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, Scardone M, et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005; 46: 827-834.
40. Tchaikovski V, Olieslagers S, Bohmer F, Waltenberger J. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 2009; 120: 150-159.
41. Hernandez C, Zapata MA, Losada E, Villarroel M, Garcia-Ramirez M, Garcia-Arumi J, et al. Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in newly diagnosed diabetic patients. Diabetes Metab Res Rev 2010; 26: 386-392.
42. Nandy D, Mukhopadhyay D, Basu A. Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose. J Invest Med 2010; 58: 804-806.
43. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complication. Ann NY Acad Sci 2011; 1243: 88-102.
44. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-320.
45. Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008; 19: 378-384.